Insider Purchases: Inside the Buy
Tag: InsiderBuying
Can a Tiny Insider Buy at Conagra Signal the Next Big Bull?
Conagra might not be hot sauce, but it’s finally warming up. A small insider buy, strong institutional backing, and a fat dividend yield could turn this frozen-aisle veteran into a comeback story. Just keep an eye on inflation and margins — both can melt fast.
Tilray of Sunshine: CEO Bought Shares Weeks Ago — and Now Earnings Are Finally Rolling In
Tilray finally posted profits and a healthy cash flow — and insiders bought in early. Could this be the long-awaited turnaround, or just another puff of smoke?
W&T Offshore (WTI): CEO Buys Shares, But the Tide May Still Be Out
W&T Offshore (WTI): Deep Value or Deep Trouble?
Houston’s oil-and-gas veteran has been drilling for 40 years — and shareholders are still waiting to strike gold. With the CEO buying more shares while shorts circle overhead, the battle for the Gulf of America’s future is heating up. Production’s up, cash flow’s steady, and the dividend still drips — but with a stock 97% below its all-time high, is this a comeback story or a cautionary tale?
AngioDynamics (ANGO)’s CEO Bought Shares a Year Ago and Stock Doubled Since: Will They Keep Going Higher?
AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?
Keurig Dr Pepper (KDP) Insiders Have Been Buying Shares. What’s Brewing?
Insiders are brewing confidence in Keurig Dr Pepper (KDP) with fresh stock buys, while institutions are holding heavy. With a mega coffee deal, spinoff plans, and steady results, is this stock about to perk up or get watered down?
Can Freshpet Make for a Fresh Buy: Insiders & Directors Think So
Freshpet’s stock has tumbled more than 70% from its highs, but insiders keep buying and Wall Street funds are all-in (119% ownership!). With revenue growing, profitability improving, and valuation looking much more reasonable, is this the turnaround treat investors have been waiting for? 🐾🍖
Salesforce (CRM): Insider Buys, AI Clouds, and Customer Armies — Should You Join the Ride?
Salesforce insiders are buying, AI is booming, and institutions are all-in. But is CRM stock really ready to rebound — or just blowing more cloud smoke? ☁️💸
Coty Class A (COTY): When Perfume Meets Portfolio
Coty’s stock is trading like discount lipstick, but insiders — including the CEO — are buying big. Is this a makeover moment or another smudge?
Eastman Chemical (EMN): Insider Chemistry at Work
Insiders from CEO to CFO are scooping up Eastman Chemical shares. With institutions owning 92% of the float and dividends flowing, is this a value play worth a reaction? 🧪📈
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?